Skip to content

Depression research published in 2024

Page 16 of 26: studies 301 to 320 of 512, newest first. Back to the depression overview

Studies

Guidelines for ketamine use in clinical psychiatry practice.

BJPsych Open May 10, 2024 Luke A. Jelen, Rupert McShane, Allan H. Young 7 citations

In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to...

The impact of mindfulness therapy combined with mentalization-based family therapy on suicidal ideation in adolescents with depressive disorder: randomized intervention study.

Annals of General Psychiatry May 8, 2024 Xiao-Fen Fan, Ju-Yi Peng, Li Zhang et al. 13 citations

Adolescents with depression who engage in non-suicidal self harming behaviors are more likely to adopt negative coping strategies when faced with negative events. Therefore, these patients should be introduced to positive coping strategies. Evidences have showed that mindfulness-based interventions can positively impact the psychology of patients with mental disorders. This study was to explore...

Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial.

BMC Psychiatry May 7, 2024 Ahmad Zolghadriha, Afagh Anjomshoaa, Mohammad Reza Jamshidi et al. 24 citations Retracted

Major depressive disorder (MDD) is the most disabling and burdensome mental disorder, negatively affecting an individual's quality of life and daily functioning. the current study was conducted with the aim of investigating the clinical effects of intravenous ketamine on symptoms of MDD and suicidal ideation. The current randomized clinical trial was carried out on 64 patients diagnosed with...

Integrating Virtual Mindfulness-Based Stress Reduction Into Inflammatory Bowel Disease Care: Mixed Methods Feasibility Trial.

JMIR Formative Research May 6, 2024 Kaitlyn Delaney Chappell, Diana Meakins, Melanie Marsh-Joyal et al. 5 citations

Individuals with inflammatory bowel disease (IBD) experience cycles of aggressive physical symptoms including abdominal pain, diarrhea, and fatigue. These acute symptoms regress and return, and chronic symptoms and complications often linger. The nature of the disease can also cause individuals to experience psychological distress including symptoms of anxiety and depression; however, unlike...

EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

BMJ May 4, 2024 2 citations

The journal and the authors are investigating the problem.The study analysed data from randomised trials of psilocybin for the treatment of depression in adults.A methodological concern has been raised about an error in the calculation of standardised mean differences.This is likely to have overestimated the benefits of psilocybin.The authors are reviewing and responding to the error and its...

DOI: 10.1136/bmj.q1025 (opens in new tab) Full text (opens in new tab) Psilocybin Meta-analysis Depression economics Clinical trial +3

Is mindfulness associated with lower online trolling among adolescents? Mediating effects of self-esteem and depression and moderating effect of dark personality traits

Journal of Psychology in Africa May 3, 2024 Fang Li, Xu Tang, X. Ge et al.

We investigated the relationship between mindfulness and online trolling among adolescents. We also explored the mediating role of self-esteem and depression and the moderating role of dark personality traits in the relationship between mindfulness and online trolling. Chinese adolescents (n = 696; female = 47.1%, mean age = 14.315 ± 1.353 years) completed measures of mindfulness, self-esteem,...

Personality traits explain the relationship between psychedelic use and less depression in a comparative study.

Scientific Reports May 3, 2024 David Sjöström, Emma Claesdotter-Knutsson, Petri Kajonius 16 citations

Interest in psychedelics is increasing due to the potential for improved mental health and quality of life. However, adverse effects on mental health are still a concern. Personality traits have been suggested to both influence the psychedelic experience and mental health, and even be changed by psychedelic use. The present study describes for the first time a national sample of Swedish...

DOI: 10.1038/s41598-024-60890-1 (opens in new tab) Full text (opens in new tab) Drug use Mental health Personality traits Psychedelics

Ketamine for Postpartum Depression: A Systematic Review

Research Posters May 2, 2024 Jaylyn Thompson, David F Lo, Alexis Foschini et al.

The purpose of this review is to explore perinatal ketamine’s potential for reducing postpartum depression after cesarean section. Articles reviewed from Pubmed, Cochrane, and Web of Science using specific search terms. 8 final papers were used for review after excluding duplicates and irrelevant titles and abstracts. Ketamine showed potential in reducing postpartum depression symptoms post...

Mindfulness-based intervention for hypertension patients with depression and/or anxiety in the community: a randomized controlled trial.

Trials May 2, 2024 Hailiang Zhang, Xiangrong Zhang, Xiaomei Jiang et al. 19 citations

To evaluate mindfulness-based intervention for hypertension with depression and/or anxiety. 10-week mindfulness-based intervention, including health education for hypertension, exclusively for the control group, was administered to the intervention group to assist sixty hypertension patients with depression/anxiety. Among them, the intervention group comprised 8 men and 22 women, with a mean...

At the Forefront: Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse

Social Work May 2, 2024 Claire Parker, Bethany Wood 2 citations

Abstract This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD,...

Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.

Journal of the American Academy of Child & Adolescent Psychiatry May 2024 Yanling Zhou, Xiaofeng Lan, Chengyu Wang et al.

Suicide is a major cause of death in adolescents with limited treatment options. Ketamine and its enantiomers have shown rapid anti-suicidal effects in adults with major depressive disorder (MDD), but their efficacy in adolescents is unknown. We conducted an active, placebo-controlled trial to determine the safety and efficacy of intravenous esketamine in this population. A total of 54...

Editorial: Novel Approaches to the Treatment of Suicidality and Depression in Youth.

Journal of the American Academy of Child & Adolescent Psychiatry May 2024 Graham J Emslie

Suicide continues to be a major cause of mortality in adolescents with limited treatment options.1,2 Effective treatments, both therapy and medication, are available for treating depression, but even with the best combination, treatment remission rates are low.3 The most common approach to treating suicidality, which includes suicidal ideation and suicidal behavior, is to address concomitant...

"Vine of the Soul": The Potential of Ayahuasca for Reducing Depression, Anxiety, and Stress among Ceremony Participants and the Role of Rumination

May 1, 2024 Banan Ramarushton

Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and has been identified as a transdiagnostic factor due to its association with multiple forms of psychopathology. A renaissance of psychedelic research shows promise in treating psychopathology with potential for acting on ruminative processes. Despite the growing interest and developments in...

Effects of mindfulness-based interventions (MBIs) on depression in pregnant women: A systematic review and meta-analysis.

Journal of Affective Disorders May 1, 2024 Chuntana Reangsing, Sasinun Punsuwun, Sarah Oerther 16 citations

We synthesized the effects of mindfulness-based interventions (MBIs) on depression in pregnant women. Ten electronic databases were searched from inception to September 2022. We reviewed studies on outcomes for pregnant women with depression receiving mindfulness-based interventions. We only reviewed studies written in English. A random-effects model was used to compute the effect size. Funnel...

DOI: 10.1016/j.jad.2024.02.049 (opens in new tab) Full text (opens in new tab) Depression Mindfulness-based interventions Pregnant women Meta-analysis

Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.

Psychiatry Research May 1, 2024 Balwinder Singh, Sagar V Parikh, Jennifer L. Vande Voort et al. 18 citations

This nonrandomized, multicenter, open-label clinical trial explored the impact of intravenous (IV) ketamine on cognitive function in adults (n = 74) with treatment-resistant depression (TRD). Patients received three IV ketamine infusions during the acute phase and, if remitted, four additional infusions in the continuation phase (Mayo site). Cognitive assessments using the Repeatable Battery...

DOI: 10.1016/j.psychres.2024.115829 (opens in new tab) Full text (opens in new tab) Neurocognition Open-label study Rbans Ketamine infusion +4

IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital.

Psychiatry Research May 1, 2024 Gilmar Gutierrez, Melody J Y Kang, Gustavo Vazquez 12 citations

Individuals with major depressive disorder and treatment resistant depression (MDD-TRD) have limited and sometimes poorly tolerated therapeutic options. Low dose ketamine has presented promising and potent antidepressant effects in this population. To support the existent literature, we conducted a longitudinal study examining five years of real-world clinical data on the use of IV low-dose...

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.

Journal of Psychiatric Research May 1, 2024 Michael Colla, Benjamin Offenhammer, Hanne Scheerer et al. 23 citations

We investigated the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in patients suffering from treatment-resistant depression (TRD) as add-on therapy. Patients were randomized to an additional 160 mg/day or 240 mg/day KET01 or placebo for 14 days. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from...

DOI: 10.1016/j.jpsychires.2024.03.002 (opens in new tab) Full text (opens in new tab) Depression Ketamine therapy Mental health treatment Clinical trials +1

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.

Psychiatry Research May 1, 2024 Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al. 12 citations

Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking. Herein, we aim to inform prediction models of non-response to ketamine/esketamine in adults with TRD. This is a retrospective analysis of PHQ-9 item response data from 120 patients with TRD who received repeated doses of...

[Clinical management of treatment-resistant depression].

Der Nervenarzt May 1, 2024 Bernhard T Baune, Sarah E Fromme, Maximilian Kiebs et al. 1 citation

Treatment-resistant depression (TRD) is a complex disorder. Although no standardized definition has been established to date, there are promising and well-established treatment options for the condition. Looking at the current pharmacological and neuromodulatory strategies, there is an urgent need for fast-acting and well-tolerated treatment options. The search for new mechanisms of action goes...

DOI: 10.1007/s00115-024-01647-z (opens in new tab) Full text (opens in new tab) Experimental treatment Glutamatergic system Off-label use Pharmacological therapy +6